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Leukocyte extravasation is a ﬁnely tuned process, in which transmigration is the ﬁnal step. Transmigration de-
pends on molecules located at borders of endothelial cells; e.g., junctional adhesion molecules (JAM-A, -B and -C).
In vivo blockade of JAM-A lead to decreased migration of monocytes into the skin. In contrast, the role of JAM-B
and -C in development of cutaneous inﬂammation is unknown. We therefore elicited an allergic contact dermatitis
in mice using 2,4-dinitro-1-ﬂuorobenzene. RT-PCR and immunoﬂuorescent staining of healthy skin revealed
a constitutive JAM-B (66.4%  6.7% of all vessels) and -C expression (88.6  13.2%), which remained constant
after induction of contact dermatitis. Functional studies, in which either JAM-B or -C neutralizing antibodies
were injected into sensitized mice prior to allergen challenge showed a concentration-dependent reduction of
the contact dermatitis. Decreased ear swelling was accompanied by reduction of leukocyte inﬁltration as analyzed
by hematoxylin and eosin (H&E) histology and enzyme activity. Combined antibody treatment at doses of 1.25 mg
per kg bodyweight lead to additive inhibition of allergic contact dermatitis, indicating that JAM-B and -C may
have distinct functions. In conclusion, interactions with JAM-B and -C are essential for development of
cutaneous inﬂammation.
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The extravasation of leukocytes into the skin is required for
immune surveillance. Unrestrained extravasation, however,
plays a key role for a number of inflammatory skin disorders,
e.g., psoriasis, allergic, or contact dermatitis. The finely
regulated process of leukocyte homing involves several
well-defined steps (Butcher and Picker, 1996; von Andrian
and Mackay, 2000; Scho¨n et al, 2003): It is initiated by short-
lived adhesive interactions of endothelial selectins with leu-
kocyte carbohydrate ligands displayed on glycoprotein
scaffolds. These interactions slow down leukocytes, which
then roll along the endothelium. Rolling allows a chemokine-
mediated interaction of leukocytes with endothelial cells,
which may lead to leukocyte activation, resulting in an
increased integrin avidity (Kishimoto et al, 1989; Lollo et al,
1993). This permits firm adhesion of leukocyte integrins to
the endothelial ligands, mostly of the immunoglobulin su-
perfamily (Butcher and Picker, 1996). Adhering leukocytes
leave the circulation by passing between endothelial
cells at their borders (Dejana et al, 1995). Six molecules
(PECAM-1, CD99, VE-cadherin, junctional adhesion mole-
cules (JAM)-A, -B and -C) are concentrated at the lateral
borders of the endothelial cells and seem to be involved in
leukocyte transmigration (Mu¨ller, 2003; Weber, 2003; Scho¨n
and Ludwig, 2005). Blockade of either PECAM-1 or CD99 in
mice with antibodies leads to a 90% reduction of leukocyte
transmigration in vivo. In contrast, treatment of mice with a
VE-cadherin antibody increased vascular permeability and
accelerated the entry of neutrophils into chemically in-
flamed mouse peritoneum, suggesting that opening of
VE-cadherin mediated endothelial cell contacts may be a
relevant step during neutrophil extravasation (Gothsch et al,
1997). In vivo antibodies against JAM-A reduced leukocyte
extravasation in a cytokine-induced meningitis (Del Maschio
et al, 1999) and in the air-pouch model (Martin-Padura et al,
1998). In contrast, the same antibody failed to inhibit
leukocyte homing in viral or bacterial meningitis models
(Lechner et al, 2000). The contribution of JAM-B and -C to
leukocyte extravasation to the skin in vivo is not known. The
expression pattern and ligand-interactions of JAM-B and
-C, however, indicate a role of these JAM in leukocyte ex-
travasation. JAM-B and -C are strongly expressed by end-
othelial cells of high endothelial venules—the predominant
site of leukocyte extravasation (Butcher and Picker, 1996).1Both authors contributed equally to this work.
Abbreviations: CHS, contact hypersensitivity; DNFB, 2,4-dinitro-
1-fluorobenzene; JAM, junctional adhesion molecules
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
969
In addition, JAM-B and -C bind to the leukocyte integrins
VLA-4 or Mac-1, respectively (Cunningham et al, 2002;
Santoso et al, 2002). In vitro studies using either JAM-B
neutralizing antibodies or soluble JAM-B support this
hypothesis: Both substances reduced leukocyte transmi-
gration across human umbilical vein endothelial cells (John-
son-Leger et al, 2002).
In an attempt to determine the contribution of JAM-B and
-C in leukocyte homing to the skin, we assessed expression
patterns on protein and mRNA levels in healthy and in-
flamed (contact dermatitis) skin, and evaluated the impact
of JAM-B and -C on leukocyte extravasation to the skin
using a mouse model of allergic contact dermatitis.
Results
JAM-B and -C are constitutively expressed in murine
skin To quantify the mRNA expression of JAM-B and -C
during development of a contact hypersensitivity (CHS) re-
sponse, expression of JAM-B and -C was evaluated in
vehicle treated and challenged skin using real-time PCR. At
all time points, expression of JAM-B and -C mRNA remained
constant in challenged ears and were similar to expression
patterns of vehicle treated ears, indicating that both JAM
molecules have not been up regulated during CHS (Table I).
We then examined the expression of JAM-B and -C pro-
teins at vessels of murine skin, staining specimen from nor-
mal and 2,4-dinitro-1-fluorobenzene (DNFB)-challenged
mouse skin with JAM-B and -C antibodies. JAM expres-
sion was visualized using fluorescent-labeled secondary
antibodies, and vessels were identified by their CD31 ex-
pression. We observed a constitutive high expression of
both JAMs in healthy murine skin, which remained constant
24 h after induction of a CHS using DNFB (Fig 1). In normal
skin, 66.4%  6.7% of all vessels expressed JAM-B, which
was almost identical in sections from DNFB-challenged skin
(68.5%  5.4%; p¼NS; t test). Over 80% of all vessels in
normal and inflamed skin expressed JAM-C (86.6%  13.2%
(normal) vs 85.9%  15.2% (inflamed); p¼NS; t test).
JAM-B and -C are required for development of a
CHS Next, we evaluated the impact of inhibitory JAM-B
and -C antibodies on the development of cutaneous in-
flammation in a murine model of CHS. Mice were sensitized
with DNFB and treated with different doses of JAM-B and/
or -C inhibitory antibodies 60 min prior to challenge with
DNFB. In the control experiments, treatment with either rat-
IgG isotype control antibody, goat IgG or both control
antibodies had no effect on ear swelling (ear swelling re-
sponses: 20.9  11.9, 20.9  9.0, 22.6  15.3 and 16.7 
2.4 cm  103 for untreated, rat and goat IgG isotype con-
trols or both control antibodies). In contrast, application of
either anti-JAM-B or anti-JAM-C antibody resulted in a sig-
nificant and concentration dependent, but not complete in-
hibition of ear swelling. Although treatment with low doses
(1.25 mg per kg) of anti-JAM-B or -C antibody did not lead
to a statistically significant reduction in ear swelling, higher
doses (2.5 mg per kg) of these antibodies had a statistically
significant effect on ear swelling. Further increase of anti-
body concentration to 5.0 mg per kg had no additional ef-
fect for both antibodies investigated (Fig 2). Reduction of
ear swelling responses in mice treated with 2.5 mg per kg
antibody was accompanied by reduction of total leukocyte
infiltration as analyzed by hematoxylin and eosin (H&E) his-
tology (Fig 3).
To gain further insight into the leukocyte populations
affected by either antibody treatment, sections were
also stained with antibodies specific for CD3, neutrophils
and macrophages/monocytes. Whereas JAM-B antibody
(2.5 mg per kg) treatment significantly reduced epidermal
CD3 staining and neutrophil infiltration, JAM-C blockade
(2.5 mg per kg) additionally reduced dermal CD3 staining,
suggesting a differential contribution of JAM-B and -C
for cutaneous inflammation. In support of this hypothesis,
peroxidase- and elastase-activity showed even more
diverse results: Activity of both enzymes was reduced
in mice treated with 2.5 mg per kg antibody. In contrast
to JAM-C antibody treatment (1.25 mg per kg), injection of
an identical dose of anti-JAM-B lead to a significant
decrease in peroxidase and elastase activity. With respect
to the nature of experiments using antibodies, this may in-
dicate that JAM-B might be predominantly involved in
neutrophil extravasation (Fig 4).
To exclude that observed changes in ear swelling and
infiltration are due to alterations in leukocyte counts caused
by application of the antibodies, a differential blood count
was performed after treatment with antibodies. Injection of
either one of the anti-JAM or isotype antibodies at 2.5 mg
per kg bodyweight lead to a significant leukopenia, which
was due to a reduction of the lymphocyte population. No
significant difference, however, was observed between the
different treatment groups. Erythrocyte and platelet count
remained constant at the investigated time points (plus 4
and 24 h) after antibody injection (not shown). As no differ-
ence in differential blood count were observed between
isotype and JAM antibody-treated mice, the changes in
ear swelling and infiltration were not due to changes in
leukocyte counts.
Table I. JAM-B and -C mRNA expression patterns remain
constant during development of a CHS response
Fold expression of HPRT
t¼0 h t¼ 3 h t¼6 h t¼ 24 h t¼ 48 h
JAM-B
Vehicle 0.83 1.12 1.01 1.40 0.85
CHS 0.84 1.17 0.80 1.10 0.70
JAM-C
Vehicle 0.31 0.34 0.45 0.27 0.23
CHS 0.30 0.39 0.32 0.29 0.21
Specimen from three mice were pooled and analyzed for JAM-B and
-C mRNA expression in vehicle and DNFB treated ears for each time
point (after DNFB challenge) indicated. Gene expression was calculated
compared to HPRT expression. At all time points no significant difference
in JAM-B or -C expression was detected, and expression of both JAM
remained constant over the period investigated.
JAM, junctional adhesion molecule; CHS, contact hypersensitivity;
DNFB, 2,4-dinitro-1-fluorobenzene; HPRT, hypoxanthine-guanine phos-
phoribosyl transferase.
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Combined treatment with JAM-B and -C antibodies has
additive anti-inﬂammatory effects As JAM-B and -C bind
to different ligands they may play distinct roles in leukocyte
extravasation. Consequently, combined inhibition of these
JAM may lead to additive or synergistic effects. We there-
fore evaluated the impact of simultaneous JAM-B and -C
antibody-treatment prior to challenge with DNFB. Injection
of JAM-B and -C antibodies at concentrations of 2.5 mg per
kg bodyweight had no additional effect compared to JAM-B
or -C blockade alone (Table II and Fig 5). Combined treat-
ment with concentrations which if applied separately, how-
ever, failed to show any effects on CHS responses (1.25 mg
per kg) lead to a marked decrease in ear swelling (Table II
and Fig 5). The reduction in ear swelling in mice treated with
JAM-B or -C (1.25 mg per kg) was 34.1% and 28.3%
(p¼NS vs appropriate isotype controls, ANOVA on ranks).
Hence, a combined blockade of JAM-B and -C has additive
effects (Fig 6).
Discussion
Leukocyte extravasation is mediated by interactions of le-
ukocytes with endothelial cells in a stepwise process, which
is initiated by leukocyte rolling and completed with trans-
migration across the endothelial barrier (von Andrian and
Mackay, 2000; Scho¨n et al, 2003; Weber, 2003). The ad-
hering leukocytes leave the circulation by passing between
endothelial cells at their borders (Dejana et al, 1995). Yet,
the molecular mechanisms of this process are far from be-
ing completely understood. Recently, JAM-A has been
shown to be involved in leukocyte transmigration in a
number of in vivo models (Martin-Padura et al, 1998; Del
Maschio et al, 1999). In contrast, the contribution of JAM-B
and -C to leukocyte extravasation to the skin in vivo is not
known. Our results provide the first evidence that JAM-B
and -C play a role in leukocyte extravasation to the skin.
The recently described differential expression of the JAMs
also support the idea, that JAM-B and -C are involved in
leukocyte extravasation to sites of inflammation. In contrast
to JAM-A, JAM-B and -C are highly expressed at HEV
(Aurrand-Lions et al, 2001), the predominant site of leu-
kocyte extravasation (Butcher and Picker, 1996). In addition,
JAM-B and -C bind to the leukocyte integrins VLA-4 or
Mac-1, respectively (Cunningham et al, 2002; Santoso et al,
2002). In vitro studies using either JAM-B antibodies or
soluble JAM-B support this hypothesis. Both substances
reduced leukocyte transmigration across human umbilical
vein endothelial cells (Johnson-Leger et al, 2002). Similar
results were obtained in recent studies investigating the
role of JAM-C in leukocyte transmigration in vitro and in vivo
(Chavakis et al, 2004; Zen et al, 2004). Furthermore, despite
the constant expression during a cutaneous inflamma-
Figure 1
Junctional adhesion molecule (JAM)-B and -C
expression in murine skin. Normal and in-
flamed (CHS) mouse skin were stained with
JAM-B or -C antibodies (green) as outlined in
Materials and Methods. Vessels were identified
by their expression of CD31 (red). In normal skin
66.4%  6.7% and 86.6%  13.2% all vessels
expressed JAM-B or -C respectively. Develop-
ment of a CHS had no effect on the expres-
sion of both JAM-B and -C (68.5%  5.4%
or 85.9%  15.2%, t test, n¼3 mice/group).
As staining with isotype control, antibody
showed fluorescence in the epidermal layer, ep-
idermal staining has to be considered unspecific.
Exemplary, arrows indicate vessels staining for
CD31 or JAM only (red or green, respectively)
and double positive staining vessels (orange).
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Figure 2
Ear swelling in 2,4-dinitro-1-fluorobenzene (DNFB)-induced contact hypersensitivity (CHS) is reduced in mice treated with either junctional
adhesion molecule (JAM)-B or -C antibodies. Mice were sensitized with DNFB and treated with indicated doses of JAM-B and/or -C function
blocking antibodies one hour before challenge. Data shown corresponds to the difference in ear swelling 24 h after challenge with DNFB or solvent.
(A) Ear swelling response in mice treated with either 2.5 mg per kg JAM-B antibody or an appropriate control antibody at the same dose. (B)
Inhibition of ear swelling with anti-JAM-B antibody is dose dependent. Although 1.25 mg per kg bodyweight have no significant effect on ear
swelling, 2.5 mg per kg profoundly inhibit the inflammatory response after DNFB challenge. Further increase of antibody dose has no additional
effect. C and D show the results for experiments using a JAM-C antibody and are otherwise similar to A and B. Six to eight mice per group were
investigated. po0.05 (t test) compared to isotype control antibodies. (E) Persistant effects of JAM-B-, JAM-C- or combined JAM-B/-C-blockade:
Mice were treated with either isotype (1.25 mg per kg or 2.5 mg per kg), JAM-B (2.5 mg per kg), JAM-C (2.5 mg per kg) or JAM-B/-C (1.25 mg per kg)
antibodies. Ear swelling responses were evaluated 24, 48, 72 and 96 h after reexposition with DNFB. Significant ear swelling responses persisted
until 72 h past reexposition, whereas at 96 h no significant differences were observed (not shown). Treatment of C57Bl/6 mice with 2.5 mg per kg
JAM-B or -C antibody, as well as using a combination of JAM-B and -C (each at 1.25 mg per kg) lead to an inhibition of ear swelling lasting 48 h after
reexposition. At 72 h, no significant effect of either antibody treatment is observed, which is most likely due to the relatively small, jet significant,
difference in ear swelling in the isotype antibody treated mice. Data from five mice per experimental condition. po0.05 (one-way ANOVA,
Bonferroni procedure) against appropriate isotype control antibodies treated animals.
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tion (Fig 1), JAM-B and -C may contribute to constitu-
tive leukocyte extravasation, required for maintenance
of immunosurveillance (Dailey, 1998) and may also show
activation-depended changes in phosphorylation or locali-
zation, as described for JAM-A (Ozaki et al, 1999,
2000).
Hence, we treated sensitized mice with JAM-B or -C
antibodies before challenge with DNFB. Both antibodies
inhibited the CHS response in a dose depended manner.
Side by side titration of antibody effects showed, that both
antibodies had a similar influence on ear swelling. Indicat-
ing, that antibody effects can be compared despite their
Figure 3
Leukocyte infiltration in 2,4-dinitro-1-fluorobenzene (DNFB)-induced contact hypersensitivity (CHS) is reduced in mice treated with either
junction adhesion molecule (JAM)-B or -C antibodies. Mice were sensitized with DNFB and treated with of JAM-B and/or -C function blocking
antibodies (2.5 mg per kg) just before challenge. 24-h after reexposition specimen from ears were stained with hematoxylin and eosin (H&E) and
immunohistochemisty was performed (CD3, clone 7/4 (neutrophils) and MOMA-2 (macrophages/monocytes). To evaluate infiltration/staining in-
tensity slides were analyzed by two pathologists unaware of the applied treatment protocol and assigned a score ranging from one to four,
corresponding to no, mild, moderate or severe infiltration/staining, respectively. Numbers in lower right indicates the average score (mean  stand-
ard deviation) of all animals per group (n¼ 6). po0.05 (t test) compared to the corresponding isotype antibody treated group.
Figure4
Reduction of contact hypersensitivity (CHS) in mice treated with
junctional adhesion molecule (JAM)-B or -C antibodies is accom-
panied with reduced neutrophil infiltration. Mice were sensitized with
2,4-dinitro-1-fluorobenzene and treated with different doses of JAM-B
and/or -C function blocking antibodies just before challenge (n¼6/
group). Peroxidase and elastase activity, corresponding to total and ne-
utrophil granulocyte infiltration, respectively, were analyzed in normal
and challenged ears. The difference of peroxidase and elastase activity
(normal vs inflamed ear) is expressed in relation to the difference in mice
treated with the appropriate control antibodies (Ab) (normal vs inflamed
ear). No difference was detected in untreated and isotype Ab-treated
specimen (not shown). po0.05 (ANOVA on ranks, Dunn’s method).
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different nature (monoclonal vs. polyclonal). This in mind,
JAM-B- and -C-antibodies seem to have differential effects
on the CHS: Although 1.25 mg per kg b.w. anti-JAM-B or
anti-JAM-C antibody failed to significantly reduce ear swell-
ing, the same dose of anti JAM-B antibody lead to a sig-
nificant decrease in neutrophil infiltration (peroxidase and
elastase activity), which was not the case for anti-JAM-C
treatment (Fig 4). Thus, JAM-B may predominately govern
neutrophil transmigration, whereas JAM-C may govern ed-
ema formation. The idea, that JAM-B and -C have overlap-
ping, but distinct functions in regulating leukocyte
transmigration is supported by the results of combined
treatment with JAM-B- and -C antibodies: Injection of 1.25
mg per kg b.w. anti JAM-B and -C prior to challenge with
DNFB led to an additive inhibition of the CHS response.
In our study, ear swelling and leukocyte infiltration were
used as endpoints. Hence, no conclusions can be drawn on
where and how JAM-B and -C are involved in leukocyte
extravasation. JAM-B and -C may have an impact on leu-
kocyte rolling, firm adhesion and transmigration, as JAM-B
interacts with the a4b1 integrin (Cunningham et al, 2002),
which is involved in leukocyte rolling and recruitment to the
skin (Butcher and Picker, 1996). Indeed, we have gathered
preliminary data, showing, that JAM-B mediates rolling and
firm adhesion of leukocytes on endothelial cells in a flow
chamber assay (Ludwig et al, in preparation).1 In addition to
its role in transmigration JAM-C also binds the leukocyte
integrin Mac-1 (Santoso et al, 2002), which is involved in
mediating firm adhesion of leukocytes in the skin compart-
ment (Scho¨n et al, 2003). Recent work (Aurrand-Lions et al,
2005) has elegantly demonstrated, that JAM-C besides
mediating transmigration is also involved in firm adhesion of
leucocytes).
Still, further studies are required to investigate the mo-
lecular mechanisms of JAM-B and -C mediated leukocyte
homing to the skin. In summary, our data illustrates the im-
portance of JAM-B and -C in the development of cutaneous
inflammation. This makes them interesting targets for the
development of novel anti-inflammatory agents.
Materials and Methods
Induction of a murine allergic contact dermatitis reaction Male
C57BL/6 mice, aged 6–10 wk were purchased from Charles River
(Sulzfeld, Germany) and housed with food and water ad lib. Animal
experiments have been approved by the governmental adminis-
tration of Hessen (Darmstadt, Germany). An allergic contact der-
matitis (CHS) was elicited using DNFB according to standard
Table II. JAM-B and -C synergistically mediate ear swelling in a
CHS response
Ear swelling
Isotype (JAM-B and -C, both
at 2.5 mg per kg)
Anti-JAM-Bþ anti JAM-C
(1.25 mg per kg)
Anti-JAM-Bþ anti JAM-C
(2.5 mg per kg)
D (cm  103)
Mice were sensitized with DNFB and treated with indicted doses of
JAM-B and -C inhibitory antibodies 60 min before re-exposition (n¼ 6 per
group). Twenty-four hours after re-exposition, ear swelling was evaluated.
po0.05 ANOVA on ranks (Dunn’s method). No difference was observed
between untreated and isotype treated mice, as well as animals treated
with 1.25 mg per kg and 2.5 mg per kg (ANOVA on ranks).
JAM, junctional adhesion molecule; CHS, contact hypersensitivity;
DNFB, 2,4-dinitro-1-fluorobenzene.
Figure 5
Reduction of contact hypersensitivity (CHS) in mice treated with
junctional adhesion molecule (JAM)-B and -C antibodies is ac-
companied with reduced leukocyte infiltration. Mice were sensitized
with 2,4-dinitro-1-fluorobenzene and treated with different doses of
JAM-B and -C function blocking antibodies just before challenge (n¼6/
group). Peroxidase and elastase activity, corresponding to total and
neutrophil granulocyte infiltration, respectively, were analyzed in normal
and challenged ears. The difference of peroxidase and elastase activity
(normal vs inflamed ear) is expressed in relation to the difference
in mice treated with the appropriate control antibodies (normal vs
inflamed ear). po0.05 (ANOVA on Ranks, Dunn’s method).
Figure6
Combined treatment with junctional adhesion molecule (JAM)-B
and -C antibodies leads to a additive inhibition of ear swelling and
additive inhibition of neutrophil infiltration in a contact hypersen-
sitivity (CHS) response. Treatment of mice with either JAM-B or -C
antibodies at 1.25 mg per kg 60 min prior to allergen challenge had no
significant effect on ear swelling. If both antibodies were, however,
injected simultaneously, a significant reduction in ear swelling was ob-
served. This inhibitory effect was additive. Analysis was performed in
six to eight mice per group.
1Ludwig RJ, Hardt K, Hatling M, et al ; Lymphocyte rolling and
firm adhesion mediated by an interaction of JAM-B and VLA-A. In
preparation.
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protocols (Schwarz et al, 2000). In brief, mice were sensitized by
applying 75 mL of 0.5% DNFB (Sigma, Seelze, Germany) solution
(4 vol acetone/1 vol olive oil) on the back on day 0. On day 5, 20 mL
of 0.25% DNFB or vehicle was applied on the left and right ear,
respectively. 24 h after challenge, CHS response was determined
using a spring-loaded micrometer (Mitutoyo, Neuss, Germany) in a
blinded fashion. Ear swelling responses of DNFB-challenged ears
were compared to the response of the vehicle-treated ear in
sensitized animals and were expressed as centimeters  103
(mean  SD).
Quantiﬁcation of JAM-B and -C mRNA Total RNA from skin
samples was prepared using Strata Prep Total mini RNA Kit (Stra-
tagene, La Jolla, California) according to the manufacturer’s in-
struction. RNA concentration and integrity was controlled using
Agilent 2100 Caliper LabChip BioAnalyzer (Agilent Technologies,
Palo Alto, California). Synthesis of cDNA from total RNA samples
was performed with First Strand cDNA synthesis kit (Amersham
Pharmacia, Freiburg, Germany) according to the recommended
protocol. Primers and probes used were purchased from Applied
Biosystems, Darmstadt, Germany. Murine JAM-B (NM_023844)
and -C (NM_023277) are available as ‘‘Assays on demand’’, assay
numbers Mm00470197_mL and Mm00499214_mL, respectively.
Sequences are not disclosed by the provider. An ABI prism 5700
detector sequence was programmed for the initial sequence of 2
min at 501C and 10 min at 951C, followed by 40 cycles of 15s at
951C and 1 min at 601C. Each measurement was set up in trip-
licates. For each time point indicated (Table I), specimen from three
mice were pooled. Gene expression was calculated compared to
hypoxanthine-guanine phosphoribosyl transferase (HPRT) expres-
sion. Specific gene regulation was calculated by comparing aller-
gen-challenged skin with vehicle-treated skin at the respective
time points.
Evaluation of JAM-B and -C expression To measure JAM-B and
-C expression on protein level, cryostat sections from inflamed
(CHS) and normal mouse skin were assessed for their JAM-B and
-C expression (n¼ 3 for each condition). Specimens were stained
with JAM-B or -C antibodies (goat anti-mouse VE-JAM polyclonal
Ab, goat anti-mouse JAM-3 polyclonal Ab; R&D Systems, Wiesb-
aden, Germany). Alexa Fluor 488 labeled rabbit anti-goat IgG
antibodies were used to visualize the JAM (Molecular Probes,
Karlsruhe, Germany). In order to quantify JAM expression, sections
were simultaneously stained for CD31 using a PE-labeled rat anti-
mouse CD31 (clone 390, Acris, Hiddenhausen, Germany). Spec-
imen stained with appropriate isotype control antibodies served as
negative controls. The percentage of JAM-B and -C expression on
vessels sections was evaluated independently by two histologists.
Treatment of mice with JAM-B and-C antibodies Mice sensi-
tized with DNFB were i.v. treated with the following antibodies 60
min prior to challenge: Monoclonal rat anti-mouse JAM-2 (VE-JAM,
JAM-B) antibody (clone 150015), polyclonal goat anti-mouse JAM-
3 (JAM-C), rat IgG1 isotype control (clone 43414.11) and purified
goat IgG. All antibodies were purchased from R&D systems with
the exception of goat IgG (Sigma). Antibodies were diluted in
phosphate-buffered saline and mice received either 5.0, 2.5 or 1.25
mg per kg bodyweight of antibody in a volume of 100 mL. 24 h after
challenge, CHS response was determined in a blinded fashion as
ear swelling responses of DNFB-challenged ears compared to the
response of the vehicle-treated ear in sensitized animals and was
expressed as centimeters  103 (mean  SD). To evaluate the
long-term impact of antibody treatment, groups of mice were
treated with isotype, JAM-B, -C or both antibodies and ear swelling
responses were monitored at 24, 48, 72 and 96 h after re-expo-
sition. Ear swelling responses were evaluated in at least six mice
per group.
Differential blood counts To investigate if antibody treatment
lead to changes in the differential blood count, mice were treated
with either one of the antibodies used in this study at 2.5 mg per kg
bodyweight. 24 h before, 4 and 24 h past i.v. injection of antibodies
blood was drawn from the retrobulbar plexus and analyzed on
a CellDyn 3500 (Abbott, Wiesbaden, Germany). For each sub-
group analysis blood from two mice was pooled, and repeated
three times.
Evaluation of leukocyte inﬁltration Specimen from normal and
inflamed mouse skin were H&E stained and infiltration was scored
independently by two histologists and assigned a score ranging
from one to four, corresponding to no, mild, moderate or sever
infiltration, respectively. Sections were also stained for infiltration
by CD3, neutrophils and monocytes/macrophages. Six mm thick
cryostat sections were incubated with an antibody specific
for either CD3 (polyclonal rabbit, DakoCytomation, Denmark),
neutrophils (clone: 7/4, Serotec, Oxford, UK), monocytes/ma-
crophages (clone: MOMA-2, Serotec) or isotype control (clone:
LO-DNP-11, Serotec). Staining was visualized by addition of ap-
propriate second step antibodies ((a) peroxidase-conjugated goat
anti-rat IgG, Dianova, Hamburg, Germany; (b) peroxidase-conju-
gated goat anti-rabbit, Dianova), using HistoGreen Chromogen
(Linaris, Wertheim-Bettingen, Germany). In analogy to the scoring
system used for H&E-stained sections, staining was assigned a
score ranging from one to four, corresponding to no, weak, mod-
erate or strong staining, respectively. CD3-stained sections were
evaluated for epidermal and dermal expression. In addition, per-
oxidase activity, corresponding to total granulocyte infiltration, was
assessed in homogenized ear-specimen according to standard
protocols (Schottelius et al, 2002; Scha¨cke et al, 2004). Briefly,
tetramethylbenzidine (TMB) dihydrochloride was used as a sensi-
tive chromogen substrate for peroxidase. To convert TMB into
TMB dihydrochloride, 34 mL of 3.7% hydrochloric acid (equimolar)
was added to 5 mg of TMB. Then, 1 mL of dimethyl sulfoxide
(DMSO) was added. This stock solution was slowly added to so-
dium acetate–citric acid buffer (0.1 mol per L, pH 6.0) in a ratio of
1:100. Two hundred microliters of this TMB solution, 40 mL of the
homogenized sample, and 25 mL of 1 mM H2O2 were added to a
microtiter plate to start the reaction. The reaction was stopped
after 30 min with 45 mL of 1 N H2SO4. Changes in OD were mon-
itored at 450 nm at 251C against the mixture of all solutions without
the added sample homogenate. Absolute extinction numbers were
used to express peroxidase activity. Elastase activity, correspond-
ing to neutrophil infiltration (Schottelius et al, 2002), was measured
by fluorescence of 7-amino-4-methyl-coumarin (AMC) that is re-
leased from the substrate MeO–Succ–Ala–Ala–Pro–Val–AMC (Bac-
hem, Torrance, California). Homogenized samples in HTAB were
diluted 1/10 in cetrimide buffer (0.3% cetrimide, 0.1 M Tris, and 1 M
NaCl, pH 8.5). The substrate MeO–Succ–Ala–Ala–Pro–Val–AMC
(300 mM in DMSO) was diluted 1/100 in cetrimide buffer to a
working concentration of 3 mM. In cetrimide buffer, diluted sam-
ples were pipetted in multiwell plates, and the reaction was started
by addition of the AMC substrate at 371C. The reaction was
stopped after 1 h with ice-cold 100 mM Na2CO3, and samples
were measured in a Spectra Max Gemine (Molecular Devices,
Menlo Park, California) at 380 nm and compared against a stand-
ard curve with the AMC standard 7-amino-4-methylcoumarin (5
mM in ethanol). For each parameter investigated, at least six an-
imals per group were investigated.
Statistical analysis Was performed using SigmaStat (SPSS, Chi-
cago, Illinois). The methods used for evaluation of statistical sig-
nificance are indicated at figure and table legends. p-Values of
o0.05 were considered as statistically significant.
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